Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada s sentinel surveillance network, January 2014

Euro Surveill. 2014 Feb 6;19(5):20690. doi: 10.2807/1560-7917.es2014.19.5.20690.

Abstract

The 2013/14 influenza season to date in Canada has been characterised by predominant (90%) A(H1N1)pdm09 activity. Vaccine effectiveness (VE) was assessed in January 2014 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically-attended laboratory-confirmed influenza A(H1N1)pdm09 infection was 74% (95% CI: 58-83). Relative to vaccine, A(H1N1)pdm09 viruses were antigenically similar and genetically well conserved, with most showing just three mutations across the 50 amino acids comprising antigenic sites of the haemagglutinin protein.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Canada / epidemiology
  • Case-Control Studies
  • Child
  • Child, Preschool
  • Female
  • Hemagglutination Inhibition Tests
  • Humans
  • Infant
  • Influenza A Virus, H1N1 Subtype / genetics
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza A Virus, H1N1 Subtype / isolation & purification*
  • Influenza Vaccines / administration & dosage*
  • Influenza Vaccines / immunology
  • Influenza, Human / diagnosis
  • Influenza, Human / epidemiology*
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Nasopharynx / virology
  • Nose / virology
  • Outcome Assessment, Health Care
  • Real-Time Polymerase Chain Reaction
  • Seasons
  • Sensitivity and Specificity
  • Sentinel Surveillance*
  • Sequence Analysis, DNA
  • Vaccination / statistics & numerical data

Substances

  • Influenza Vaccines